X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AJANTA PHARMA with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AJANTA PHARMA   ACTAVIS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
ACTAVIS
Dec-14
AJANTA PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,81819,142-   
Low Rs1,10611,676-   
Sales per share (Unadj.) Rs239.53,447.0-  
Earnings per share (Unadj.) Rs52.8-430.2-  
Cash flow per share (Unadj.) Rs59.5316.3-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs230.07,476.4-  
Shares outstanding (eoy) m88.77265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.14.5 136.6%   
Avg P/E ratio x27.7-35.8 -77.3%  
P/CF ratio (eoy) x24.648.7 50.4%  
Price / Book Value ratio x6.42.1 308.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m129,7824,097,341 3.2%   
No. of employees `0006.821.6 31.5%   
Total wages/salary Rs m3,7650-   
Avg. sales/employee Rs Th3,128.442,433.4 7.4%   
Avg. wages/employee Rs Th554.00-   
Avg. net profit/employee Rs Th689.7-5,295.2 -13.0%   
INCOME DATA
Net Sales Rs m21,258916,561 2.3%  
Other income Rs m242-2,288 -10.6%   
Total revenues Rs m21,499914,273 2.4%   
Gross profit Rs m6,584117,745 5.6%  
Depreciation Rs m596198,469 0.3%   
Interest Rs m428,910 0.0%   
Profit before tax Rs m6,226-111,921 -5.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,210 0.0%   
Tax Rs m1,539-5,754 -26.7%   
Profit after tax Rs m4,686-114,377 -4.1%  
Gross profit margin %31.012.8 241.1%  
Effective tax rate %24.75.1 480.9%   
Net profit margin %22.0-12.5 -176.7%  
BALANCE SHEET DATA
Current assets Rs m12,236482,910 2.5%   
Current liabilities Rs m3,461352,183 1.0%   
Net working cap to sales %41.314.3 289.4%  
Current ratio x3.51.4 257.9%  
Inventory Days Days6058 103.8%  
Debtors Days Days8466 127.5%  
Net fixed assets Rs m11,140111,921 10.0%   
Share capital Rs m1770-   
"Free" reserves Rs m20,2370-   
Net worth Rs m20,4141,987,986 1.0%   
Long term debt Rs m101,041,744 0.0%   
Total assets Rs m24,4863,643,325 0.7%  
Interest coverage x1,519.4-2.9 -52,916.2%   
Debt to equity ratio x00.5 0.1%  
Sales to assets ratio x0.90.3 345.1%   
Return on assets %19.2-2.3 -816.6%  
Return on equity %23.0-5.8 -399.0%  
Return on capital %30.5-3.0 -1,013.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,0520-   
CASH FLOW
From Operations Rs m2,854157,391 1.8%  
From Investments Rs m-2,604-376,855 0.7%  
From Financial Activity Rs m-2211,738 -0.0%  
Net Cashflow Rs m248-7,726 -3.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 70.17 Rs / USD

Compare AJANTA PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare AJANTA PHARMA With: ABBOTT INDIA  FDC LTD.  BIOCON   IPCA LABS  PANACEA BIOTECH  



Today's Market

Exit Polls Pull Markets Higher; Sensex Jumps Over 800 Points(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.4% while the Hang Seng is down 0.3%.

Related Views On News

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

A 10-Bagger in Just 6 Years! The Rebirth of India Will Create More Big Winners Like This(The 5 Minute Wrapup)

May 7, 2019

How a niche tech startup battled all odds to eventually become a 10 bagger.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


May 20, 2019 11:47 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS